ELI LILLY & Business Summary

Eli Lilly & Company (LLY) operates a high-margin pharmaceutical business model centered on the discovery, development, and global commercialization of innovative molecular therapies. Revenue is primarily generated through product sales across four core therapeutic segments: Cardiometabolic Health, Oncology, Immunology, and Neuroscience. As of early 2026, the company’s growth is aggressively fueled by its incretin franchise, specifically Mounjaro and Zepbound, which dominate the diabetes and obesity markets. Lilly has significantly expanded its manufacturing footprint with over $55 billion in capital commitments since 2020 to meet surging demand for GLP-1 and GIP receptor agonists. Direct competitors include Novo Nordisk, Pfizer, Amgen, and Viking Therapeutics; Lilly currently maintains a dominant market position, holding approximately 60% of the U.S. incretin market and is projected to lead the global pharmaceutical industry by total revenue in 2026. Founded in 1876 by Colonel Eli Lilly, the company is currently led by Chair and CEO David A. Ricks, who has overseen its transformation into the world’s most valuable healthcare entity. The executive leadership team includes Lucas Montarce as EVP and CFO, a 25-year veteran of the firm, and Dr. Daniel Skovronsky, who serves as Chief Scientific and Product Officer and President of Lilly Research Laboratories. Recent strategic appointments to the Executive Committee include Carole Ho, M.D. (EVP and President of Lilly Neuroscience, formerly of Denali Therapeutics) and Adrienne Brown (EVP and President of Lilly Immunology). Other key leaders include Jacob Van Naarden, who heads Lilly Oncology and corporate business development, and Kenneth Custer, Ph.D., who leads the high-growth Cardiometabolic Health division. This leadership core is supported by a board of directors featuring prominent figures from the healthcare and technology sectors, including representatives from major institutional investors like Vanguard and BlackRock.